Company intelligence / Profile preview

Shenzhen JYMed Technology

Ownership: Private
Development stage: Other

Overview

JYMed is a leading Chinese peptide manufacturer and CRDMO with FDA-inspected facilities. The company produces commercial-scale generic APIs and custom peptides for pharmaceutical and cosmetic applications. Its pipeline includes both generic APIs such as semaglutide, liraglutide, tirzepatide, oxytocin acetate, vasopressin acetate, desmopressin acetate, terlipressin acetate, caspofungin acetate, micafungin sodium—many of which are already commercialized. The company has passed multiple US FDA inspections for its manufacturing plants.

Therapeutic areas: Endocrinology
Modalities: PeptidesSynthetic peptide
Industry: Contract Manufacturing Organization

Beyond the preview

Go deeper on Shenzhen JYMed Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shenzhen JYMed Technology.

Explore the full profile